Der Angiogenese-Inhibitor IM862 verbessert das Überleben beim experimentellen Pankreaskarzinom auch nach verzögertem Therapiebeginn

Abstract

IM862 is a dipeptide of L-glutamyl-L-tryptophan with antiangiogenic properties and potential antitumor activity. This study evaluated the effect of IM862 on human pancreatic cancer in vitro and in vivo. Proliferation of three pancreatic cancer cell lines (MIAPaCa-2, AsPC-1, HPAF-2) was significantly inhibited only at high concentrations of IM862 (> 100 µg/ml). In vivo, IM862 (100 mg/kg) reduced tumor size and metastasis in an orthotopic nude mouse model, thereby increasing survival, even after a delayed onset of therapy (6 weeks after tumor induction). In vitro data, reduced microvessel density in tumors, and diminished plasma concentration of the proangiogenic mediator VEGF indicate that IM862 inhibits tumor angiogenesis rather than proliferation of pancreatic cancer cells.